Senate Drug Pricing Legislation Clears Committee With Generic Exclusivity “Parking” Provision Unchanged

US Senate health committee advanced the Lower Health Care Costs Act with few pharma-related changes. Bill’s drug pricing provisions include the CREATES Act and a requirement that manufacturers report to HHS on price increases.

Capitol-building-dome-light
The Senate HELP Committee Advanced the Lowering Health Care Costs Act to the full Senate floor.

The US Senate Committee on Health, Labor Education and Pensions advanced the Lower Health Care Costs (LHCC) Act to full Senate consideration by a 20-3 vote on 26 June, leaving intact the bill's initial language on the “parking” of 180-day exclusivity.

The approved bill includes a number of provisions related to drug pricing that were unchanged from the most recent version released by the committee. One new provision added at the markup relates to enhancing transparency around price increases

More from Pricing Debate

More from Market Access